

WHO/IVR State of the Art of New Vaccines: Research and Development

References HIV vaccines

- Allen TM, Mortara L, Mothe BR, Liebl M, Jing P, Calore B, et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. *J Virol* 2002;76(8):4108-4112.
- Allen TM, O'Connor DH, Jing P, Dzuris JL, Mothe BR, Vogel TU, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. *Nature* 2000;407(6802):386-390.
- Allen TM, Vogel TU, Fuller DH, Mothe BR, Steffen S, Boyson JE, et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. *J Immunol* 2000;164(9):4968-4978.
- Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT, et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. *Nature* 2002;420(6914):434-439.
- Altman JD, Feinberg MB. HIV escape: there and back again. *Nat Med* 2004;10(3):229-230.
- Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, Horibata S, et al. Priming-boosting vaccination with recombinant *Mycobacterium bovis* bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. *J Virol* 2005;79(20):12871-12879.
- Anderson R, Hanson M. Potential public health impact of imperfect HIV type 1 vaccines. *J Infect Dis* 2005;191 Suppl 1:S85-96.
- Arthur LO, Bess JW, Jr., Chertova EN, Rossio JL, Esser MT, Benveniste RE, et al. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. *AIDS Res Hum Retroviruses* 1998;14 Suppl 3:S311-319.
- Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. *Nat Med* 2000;6(2):200-206.
- Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, Penninck D, et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. *Nat Med* 1999;5(2):194-203.
- Barbato G, Bianchi E, Ingallinella P, Hurni WH, Miller MD, Ciliberto G, et al. Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. *J Mol Biol* 2003;330(5):1101-1115.
- Barnett AL, Cunningham JM. Receptor binding transforms the surface subunit of the mammalian C-type retrovirus envelope protein from an inhibitor to an activator of fusion. *J Virol* 2001;75(19):9096-9105.
- Barouch DH, Craiu A, Kuroda MJ, Schmitz JE, Zheng XX, Santra S, et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. *Proc Natl Acad Sci U S A* 2000;97(8):4192-4197.
- Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. *Nature* 2002;415(6869):335-339.

Beddows S, Schulke N, Kirschner M, Barnes K, Franti M, Michael E, et al. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. *J Virol* 2005;79(14):8812-8827.

Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold K, Sheppard H, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. *J Infect Dis* 2001;183(9):1343-1352.

Belyakov IM, Ahlers JD, Berzofsky JA. Mucosal AIDS vaccines: current status and future directions. *Expert Rev Vaccines* 2004;3(4 Suppl):S65-73.

Belyakov IM, Hel Z, Kelsall B, Kuznetsov VA, Ahlers JD, Nacsa J, et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. *Nat Med* 2001;7(12):1320-1326.

Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. *Nature* 1990;345(6276):622-625.

Binley JM, Sanders RW, Clas B, Schuelke N, Master A, Guo Y, et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. *J Virol* 2000;74(2):627-643.

Blancou P, Chenciner N, Ho Tsong Fang R, Monceaux V, Cumont MC, Guetard D, et al. Simian immunodeficiency virus promoter exchange results in a highly attenuated strain that protects against uncloned challenge virus. *J Virol* 2004;78(3):1080-1092.

Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. *Annu Rev Med* 2002;53:557-593.

Borrow P, Lewicki H, Wei X, Horwitz MS, Pfeffer N, Meyers H, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. *Nat Med* 1997;3(2):205-211.

Boyer JD, Ugen KE, Wang B, Agadjanyan M, Gilbert L, Bagarazzi ML, et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. *Nat Med* 1997;3(5):526-532.

Brelot A, Alizon M. HIV-1 entry and how to block it. *Aids* 2001;15 Suppl 5:S3-11.

Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. *J Exp Med* 2004;200(6):749-759.

Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, et al. HIV vaccine design and the neutralizing antibody problem. *Nat Immunol* 2004;5(3):233-236.

Buve A, Bishikwabo-Nsarhaza K, Mutangadura G. The spread and effect of HIV-1 infection in sub-Saharan Africa. *Lancet* 2002;359(9322):2011-2017.

Cafaro A, Caputo A, Fracasso C, Maggiorella MT, Goletti D, Baroncelli S, et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. *Nat Med* 1999;5(6):643-650.

Calarota SA, Weiner DB. Approaches for the design and evaluation of HIV-1 DNA vaccines. *Expert Rev Vaccines* 2004;3(4 Suppl):S135-149.

Calarota SA, Weiner DB. Present status of human HIV vaccine development. *Aids* 2003;17 Suppl 4:S73-84.

Caputo A, Gavioli R, Ensoli B. Recent advances in the development of HIV-1 Tat-based vaccines. *Curr HIV Res* 2004;2(4):357-376.

Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. *Immunity* 2005;22(2):163-173.

Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. *J Virol* 2003;77(11):6305-6313.

Chakraborty H, Sen PK, Helms RW, Vernazza PL, Fiscus SA, Eron JJ, et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. *Aids* 2001;15(5):621-627.

Chan DC, Kim PS. HIV entry and its inhibition. *Cell* 1998;93(5):681-684.

Cohen J. Immunology. New virtual center aims to speed AIDS vaccine progress. *Science* 2005;309(5734):541.

Cohen J. Public health. AIDS vaccine trial produces disappointment and confusion. *Science* 2003;299(5611):1290-1291.

Crotty S, Miller CJ, Lohman BL, Neagu MR, Compton L, Lu D, et al. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. *J Virol* 2001;75(16):7435-7452.

Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. *Science* 1992;258(5090):1938-1941.

Davis NL, Caley IJ, Brown KW, Betts MR, Irlbeck DM, McGrath KM, et al. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. *J Virol* 2000;74(1):371-378.

Desmezieres E, Gupta N, Vassell R, He Y, Peden K, Sirota L, et al. Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120. *J Virol* 2005;79(8):4774-4781.

Desrosiers RC. Prospects for an AIDS vaccine. *Nat Med* 2004;10(3):221-223.

Devico A, Silver A, Thronton AM, Sarngadharan MG, Pal R. Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates. *Virology* 1996;218(1):258-263.

Devico AL, Fouts TR, Shata MT, Kamin-Lewis R, Lewis GK, Hone DM. Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. *Vaccine* 2002;20(15):1968-1974.

Doan LX, Li M, Chen C, Yao Q. Virus-like particles as HIV-1 vaccines. *Rev Med Virol* 2005;15(2):75-88.

Drobniewski FA, Balabanova YM, Ruddy MC, Graham C, Kuznetzov SI, Gusarova GI, et al. Tuberculosis, HIV seroprevalence and intravenous drug abuse in prisoners. *Eur Respir J* 2005;26(2):298-304.

D'Souza MP, Milman G, Bradac JA, McPhee D, Hanson CV, Hendry RM. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. *Aids* 1995;9(8):867-874.

Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. *Annu Rev Biochem* 2001;70:777-810.

Emini EA, Koff WC. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope. *Science* 2004;304(5679):1913-1914.

Esparza J, Osmanov S, Pattou-Markovic C, Toure C, Chang ML, Nixon S. Past, present and future of HIV vaccine trials in developing countries. *Vaccine* 2002;20(15):1897-1898.

Evans DT, Desrosiers RC. Immune evasion strategies of the primate lentiviruses. *Immunol Rev* 2001;183:141-158.

Evans DT, O'Connor DH, Jing P, Dzuris JL, Sidney J, da Silva J, et al. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. *Nat Med* 1999;5(11):1270-1276.

Excler JL, Beyrer C. Human immunodeficiency virus vaccine development in developing countries: are efficacy trials feasible? *J Hum Virol* 2000;3(4):193-214.

Feeney ME, Tang Y, Pfafferott K, Roosevelt KA, Draenert R, Trocha A, et al. HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. *J Immunol* 2005;174(12):7524-7530.

Feinberg MB, Moore JP. AIDS vaccine models: challenging challenge viruses. *Nat Med* 2002;8(3):207-210.

Ferrantelli F, Cafaro A, Ensoli B. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. *Curr Opin Biotechnol* 2004;15(6):543-556.

Ferrantelli F, Rasmussen RA, Hofmann-Lehmann R, Xu W, McClure HM, Ruprecht RM. Do not underestimate the power of antibodies--lessons from adoptive transfer of antibodies against HIV. *Vaccine* 2002;20 Suppl 4:A61-65.

Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. *Nat Med* 1999;5(5):512-517.

Forsell MN, Li Y, Sundback M, Svehla K, Liljestrom P, Mascola JR, et al. Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus. *J Virol* 2005;79(17):10902-10914.

Fouts T, Godfrey K, Bobb K, Montefiori D, Hanson CV, Kalyanaraman VS, et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. *Proc Natl Acad Sci U S A* 2002;99(18):11842-11847.

Fouts TR, Tuskan R, Godfrey K, Reitz M, Hone D, Lewis GK, et al. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. *J Virol* 2000;74(24):11427-11436.

Frahm N, Adams S, Kiepiela P, Linde CH, Hewitt HS, Lichterfeld M, et al. HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. *J Virol* 2005;79(16):10218-10225.

Franchini G, Nacsa J, Hel Z, Trynieszewska E. Immune intervention strategies for HIV-1 infection of humans in the SIV macaque model. *Vaccine* 2002;20 Suppl 4:A52-60.

Gahery-Segard H, Pialoux G, Charmeteau B, Sermet S, Poncelet H, Raux M, et al. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. *J Virol* 2000;74(4):1694-1703.

Gallo RC. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. *Proc Natl Acad Sci U S A* 1999;96(15):8324-8326.

Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, et al. Origin of HIV-1 in the chimpanzee *Pan troglodytes troglodytes*. *Nature* 1999;397(6718):436-441.

Garber DA, Silvestri G, Feinberg MB. Prospects for an AIDS vaccine: three big questions, no easy answers. *Lancet Infect Dis* 2004;4(7):397-413.

Girard M, Mastro TD, Koff WC. Human Immunodeficiency Virus. In: Plotkin SA, Orenstein WA, editors. *Vaccines*. Fourth ed ed. Philadelphia, Saunders, 2004: 1219-1258.

Girard M, Meignier B, Barre-Sinoussi F, Kieny MP, Matthews T, Muchmore E, et al. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. *J Virol* 1995;69(10):6239-6248.

Giri M, Ugen KE, Weiner DB. DNA vaccines against human immunodeficiency virus type 1 in the past decade. *Clin Microbiol Rev* 2004;17(2):370-389.

Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine. *Nat Med* 1996;2(9):960-964.

Gorny MK, Revesz K, Williams C, Volsky B, Louder MK, Anyangwe CA, et al. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. *J Virol* 2004;78(5):2394-2404.

Goulder PJ, Altfeld MA, Rosenberg ES, Nguyen T, Tang Y, Eldridge RL, et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. *J Exp Med* 2001;193(2):181-194.

Goulder PJ, Watkins DI. HIV and SIV CTL escape: implications for vaccine design. *Nat Rev Immunol* 2004;4(8):630-640.

Graham BS, McElrath MJ, Connor RI, Schwartz DH, Gorse GJ, Keefer MC, et al. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. *J Infect Dis* 1998;177(2):310-319.

Graham BS, Wright PF. Candidate AIDS vaccines. *N Engl J Med* 1995;333(20):1331-1339.

Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. *Lancet* 2001;357(9263):1149-1153.

Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. *J Virol* 2003;77(21):11708-11717.

Guan Y, Whitney JB, Detorio M, Wainberg MA. Construction and in vitro properties of a series of attenuated simian immunodeficiency viruses with all accessory genes deleted. *J Virol* 2001;75(9):4056-4067.

Hanke T, Samuel RV, Blanchard TJ, Neumann VC, Allen TM, Boyson JE, et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. *J Virol* 1999;73(9):7524-7532.

Harouse JM, Gettie A, Eshetu T, Tan RC, Bohm R, Blanchard J, et al. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). *J Virol* 2001;75(4):1990-1995.

Harvey TJ, Anraku I, Linedale R, Harrich D, Mackenzie J, Suhrbier A, et al. Kunjin virus replicon vectors for human immunodeficiency virus vaccine development. *J Virol* 2003;77(14):7796-7803.

Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, et al. Cardioliipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. *Science* 2005;308(5730):1906-1908.

Heeney JL. Primate models for AIDS vaccine development. *Aids* 1996;10 Suppl A:S115-122.

Hel Z, Nacsa J, Trynieszewska E, Tsai WP, Parks RW, Montefiori DC, et al. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. *J Immunol* 2002;169(9):4778-4787.

Hel Z, Venzon D, Poudyal M, Tsai WP, Giuliani L, Woodward R, et al. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. *Nat Med* 2000;6(10):1140-1146.

Hofmann-Lehmann R, Vlasak J, Williams AL, Chenine AL, McClure HM, Anderson DC, et al. Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. *Aids* 2003;17(2):157-166.

Horton H, Vogel TU, Carter DK, Vielhuber K, Fuller DH, Shipley T, et al. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. *J Virol* 2002;76(14):7187-7202.

Hsu M, Harouse JM, Gettie A, Buckner C, Blanchard J, Cheng-Mayer C. Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120. *J Virol* 2003;77(2):989-998.

Im EJ, Hanke T. MVA as a vector for vaccines against HIV-1. *Expert Rev Vaccines* 2004;3(4 Suppl):S89-97.

Ishioka GY, Fikes J, Hermanson G, Livingston B, Crimi C, Qin M, et al. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. *J Immunol* 1999;162(7):3915-3925.

James CO, Huang MB, Khan M, Garcia-Barrio M, Powell MD, Bond VC. Extracellular Nef protein targets CD4+ T cells for apoptosis by interacting with CXCR4 surface receptors. *J Virol* 2004;78(6):3099-3109.

Jeffs SA, Goriup S, Keble B, Crane D, Bolgiano B, Sattentau Q, et al. Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. *Vaccine* 2004;22(8):1032-1046.

Jekle A, Keppler OT, De Clercq E, Schols D, Weinstein M, Goldsmith MA. In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. *J Virol* 2003;77(10):5846-5854.

Joag SV, Adany I, Li Z, Foresman L, Pinson DM, Wang C, et al. Animal model of mucosally transmitted human immunodeficiency virus type 1 disease: intravaginal and oral deposition of simian/human immunodeficiency virus in macaques results in systemic infection, elimination of CD4+ T cells, and AIDS. *J Virol* 1997;71(5):4016-4023.

Johnson PR, Schnepf BC, Connell MJ, Rohne D, Robinson S, Krivulka GR, et al. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. *J Virol* 2005;79(2):955-965.

Johnson RP, Lifson JD, Czajak SC, Cole KS, Manson KH, Glickman R, et al. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. *J Virol* 1999;73(6):4952-4961.

Joint United Nations Programme on HIV/AIDS (UNAIDS) Report on the global AIDS Epidemic. Geneva, Switzerland: UNAIDS; 2004 December.

Kang SM, Compans RW. Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus. *J Virol* 2003;77(6):3615-3623.

Kang SM, Yao Q, Guo L, Compans RW. Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B. *J Virol* 2003;77(18):9823-9830.

Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, Ramshaw IA. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. *J Virol* 1998;72(12):10180-10188.

Kessler JA, 2nd, McKenna PM, Emini EA, Chan CP, Patel MD, Gupta SK, et al. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. *AIDS Res Hum Retroviruses* 1997;13(7):575-582.

Kim EY, Busch M, Abel K, Fritts L, Bustamante P, Stanton J, et al. Retroviral recombination in vivo: viral replication patterns and genetic structure of simian immunodeficiency virus (SIV) populations in rhesus macaques after simultaneous or sequential intravaginal inoculation with SIVmac239Deltavpx/Deltavpr and SIVmac239Deltanef. *J Virol* 2005;79(8):4886-4895.

Klausner RD, Fauci AS, Corey L, Nabel GJ, Gayle H, Berkley S, et al. Medicine. The need for a global HIV vaccine enterprise. *Science* 2003;300(5628):2036-2039.

Koch M, Pancera M, Kwong PD, Kolchinsky P, Grundner C, Wang L, et al. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. *Virology* 2003;313(2):387-400.

Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. *Br Med Bull* 2001;58:19-42.

Korber B, Muldoon M, Theiler J, Gao F, Gupta R, Lapedes A, et al. Timing the ancestor of the HIV-1 pandemic strains. *Science* 2000;288(5472):1789-1796.

Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. *J Virol* 1994;68(7):4650-4655.

Kuroda MJ, Schmitz JE, Charini WA, Nickerson CE, Lifton MA, Lord CI, et al. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. *J Immunol* 1999;162(9):5127-5133.

Kuznetsov VA, Stepanov VS, Berzofsky JA, Belyakov IM. Assessment of the relative therapeutic effects of vaccines on virus load and immune responses in small groups at several time points: efficacy of mucosal and subcutaneous polypeptide vaccines in rhesus macaques exposed to SHIV. *J Clin Virol* 2004;31 Suppl 1:S69-82.

Kuznetsov YG, Victoria JG, Robinson WE, Jr., McPherson A. Atomic force microscopy investigation of human immunodeficiency virus (HIV) and HIV-infected lymphocytes. *J Virol* 2003;77(22):11896-11909.

Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. *Nature* 2002;420(6916):678-682.

Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. *J Virol* 2003;77(19):10557-10565.

Lahti AL, Manninen A, Saksela K. Regulation of T cell activation by HIV-1 accessory proteins: Vpr acts via distinct mechanisms to cooperate with Nef in NFAT-directed gene expression and to promote transactivation by CREB. *Virology* 2003;310(1):190-196.

Lemckert AA, Goudsmit J, Barouch DH. Challenges in the search for an HIV vaccine. *Eur J Epidemiol* 2004;19(6):513-516.

Lenz O, Dittmar MT, Wagner A, Ferko B, Vorauer-Uhl K, Stiegler G, et al. Trimeric membrane-anchored gp41 inhibits HIV membrane fusion. *J Biol Chem* 2005;280(6):4095-4101.

Letvin NL, Montefiori DC, Yasutomi Y, Perry HC, Davies ME, Lekutis C, et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. *Proc Natl Acad Sci U S A* 1997;94(17):9378-9383.

Letvin NL, Robinson S, Rohne D, Axthelm MK, Fanton JW, Bilska M, et al. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope. *J Virol* 2001;75(9):4165-4175.

Letvin NL. Strategies for an HIV vaccine. *J Clin Invest* 2002;110(1):15-20.

Li Q, Duan L, Estes JD, Ma ZM, Rourke T, Wang Y, et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. *Nature* 2005;434(7037):1148-1152.

Lian Y, Srivastava I, Gomez-Roman VR, Zur Megede J, Sun Y, Kan E, et al. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. *J Virol* 2005;79(21):13338-13349.

Liang X, Casimiro DR, Schleif WA, Wang F, Davies ME, Zhang ZQ, et al. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. *J Virol* 2005;79(19):12321-12331.

Lifson JD, Rossio JL, Arnaout R, Li L, Parks TL, Schneider DK, et al. Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. *J Virol* 2000;74(6):2584-2593.

Lifson JD, Rossio JL, Piatak M, Jr., Bess J, Jr., Chertova E, Schneider DK, et al. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. *AIDS Res Hum Retroviruses* 2004;20(7):772-787.

Lifson JD, Rossio JL, Piatak M, Jr., Parks T, Li L, Kiser R, et al. Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. *J Virol* 2001;75(21):10187-10199.

Liu XL, Clark KR, Johnson PR. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus. *Gene Ther* 1999;6(2):293-299.

Lorin C, Mollet L, Delebecque F, Combredet C, Hurtrel B, Charneau P, et al. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. *J Virol* 2004;78(1):146-157.

Maggiorella MT, Baroncelli S, Michelini Z, Fanales-Belasio E, Moretti S, Sernicola L, et al. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. *Vaccine* 2004;22(25-26):3258-3269.

Markovic I, Clouse KA. Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention. *Curr HIV Res* 2004;2(3):223-234.

Mascarell L, Fayolle C, Bauche C, Ladant D, Leclerc C. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of *Bordetella pertussis*. *J Virol* 2005;79(15):9872-9884.

Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. *J Virol* 1999;73(5):4009-4018.

Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. *J Virol* 2005;79(2):771-779.

Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. *J Infect Dis* 1996;173(2):340-348.

Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. *Nat Med* 2000;6(2):207-210.

Matano T, Kano M, Nakamura H, Takeda A, Nagai Y. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen. *J Virol* 2001;75(23):11891-11896.

Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. *J Virol* 1998;72(1):164-169.

Matoba N, Magerus A, Geyer BC, Zhang Y, Muralidharan M, Alfsen A, et al. A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. *Proc Natl Acad Sci U S A* 2004;101(37):13584-13589.

Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. *Nature* 2005;434(7037):1093-1097.

McCutchan FE, Hoelscher M, Tovanabutra S, Piyasirisilp S, Sanders-Buell E, Ramos G, et al. In-depth analysis of a heterosexually acquired human immunodeficiency virus type 1 superinfection: evolution, temporal fluctuation, and intercompartment dynamics from the seronegative window period through 30 months postinfection. *J Virol* 2005;79(18):11693-11704.

McCutchan FE, Viputtigul K, de Souza MS, Carr JK, Markowitz LE, Buapunth P, et al. Diversity of envelope glycoprotein from human immunodeficiency virus type 1 of recent seroconverters in Thailand. *AIDS Res Hum Retroviruses* 2000;16(8):801-805.

McCutchan FE. In: Thompson RCA, editor. *The Molecular Epidemiology of Infectious Diseases*. London, Holder, A, 2000: 143-167.

McCutchan FE. Understanding the genetic diversity of HIV-1. *Aids* 2000;14 Suppl 3:S31-44.

McDermott AB, Mitchen J, Piaskowski S, De Souza I, Yant LJ, Stephany J, et al. Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. *J Virol* 2004;78(6):3140-3144.

McGaughey GB, Barbato G, Bianchi E, Freidinger RM, Garsky VM, Hurni WM, et al. Progress towards the development of a HIV-1 gp41-directed vaccine. *Curr HIV Res* 2004;2(2):193-204.

McMichael A, Hanke T. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? *Nat Rev Immunol* 2002;2(4):283-291.

McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. *Nature* 2001;410(6831):980-987.

McNeil JG, Johnston MI, Birx DL, Tramont EC. Policy rebuttal. HIV vaccine trial justified. *Science* 2004;303(5660):961.

Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. *J Exp Med* 2004;200(6):761-770.

Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, Wietgreffe S, et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. *J Virol* 2005;79(14):9217-9227.

Mortara L, Gras-Masse H, Rommens C, Venet A, Guillet JG, Bourgault-Villada I. Type 1 CD4(+) T-cell help is required for induction of anti-peptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques. *J Virol* 1999;73(5):4447-4451.

Nabel GJ. HIV vaccine strategies. *Vaccine* 2002;20(15):1945-1947.

Nabel GJ. Immunology. Close to the edge: neutralizing the HIV-1 envelope. *Science* 2005;308(5730):1878-1879.

Nishimura Y, Igarashi T, Haigwood N, Sadjadpour R, Plishka RJ, Buckler-White A, et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. *J Virol* 2002;76(5):2123-2130.

Nishimura Y, Igarashi T, Haigwood NL, Sadjadpour R, Donau OK, Buckler C, et al. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. *Proc Natl Acad Sci U S A* 2003;100(25):15131-15136.

O'Connor D, Friedrich T, Hughes A, Allen TM, Watkins D. Understanding cytotoxic T-lymphocyte escape during simian immunodeficiency virus infection. *Immunol Rev* 2001;183:115-126.

Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, Wyatt R, et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. *J Virol* 2004;78(19):10724-10737.

Osterhaus AD, van Baalen CA, Gruters RA, Schutten M, Siebelink CH, Hulskotte EG, et al. Vaccination with Rev and Tat against AIDS. *Vaccine* 1999;17(20-21):2713-2714.

Pantophlet R, Wilson IA, Burton DR. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. *J Virol* 2003;77(10):5889-5901.

Paris R, Bejrachandra S, Karnasuta C, Chandanayingyong D, Kunachiwa W, Leetrakool N, et al. HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting. *Tissue Antigens* 2004;64(3):251-256.

Parker CE, Deterding LJ, Hager-Braun C, Binley JM, Schulke N, Katinger H, et al. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. *J Virol* 2001;75(22):10906-10911.

Parker RA, Regan MM, Reimann KA. Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics. *J Virol* 2001;75(22):11234-11238.

Parren PW, Marx PA, Hessel AJ, Luckay A, Harouse J, Cheng-Mayer C, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. *J Virol* 2001;75(17):8340-8347.

Parren PW, Moore JP, Burton DR, Sattentau QJ. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. *Aids* 1999;13 Suppl A:S137-162.

Patterson LJ, Malkevitch N, Pinczewski J, Venzon D, Lou Y, Peng B, et al. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. *J Virol* 2003;77(16):8607-8620.

Pauza CD, Trivedi P, Wallace M, Ruckwardt TJ, Le Buanec H, Lu W, et al. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. *Proc Natl Acad Sci U S A* 2000;97(7):3515-3519.

Peeters M, Courgnaud V, Abela B, Auzel P, Pourrut X, Bibollet-Ruche F, et al. Risk to human health from a plethora of simian immunodeficiency viruses in primate bushmeat. *Emerg Infect Dis* 2002;8(5):451-457.

Peng B, Wang LR, Gomez-Roman VR, Davis-Warren A, Montefiori DC, Kalyanaraman VS, et al. Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. *J Virol* 2005;79(16):10200-10209.

Perri S, Greer CE, Thudium K, Doe B, Legg H, Liu H, et al. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. *J Virol* 2003;77(19):10394-10403.

Peterlin BM, Trono D. Hide, shield and strike back: how HIV-infected cells avoid immune eradication. *Nat Rev Immunol* 2003;3(2):97-107.

Pialoux G, Excler JL, Riviere Y, Gonzalez-Canali G, Feuillie V, Coulaud P, et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. *AIDS Res Hum Retroviruses* 1995;11(3):373-381.

Pialoux G, Gahery-Segard H, Sermet S, Poncelet H, Fournier S, Gerard L, et al. Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. *Aids* 2001;15(10):1239-1249.

Pomerantz RJ, Seshamma T, Trono D. Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency. *J Virol* 1992;66(3):1809-1813.

Poon B, Hsu JF, Gudeman V, Chen IS, Grovit-Ferbas K. Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses. *J Virol* 2005;79(16):10210-10217.

Poon B, Safrit JT, McClure H, Kitchen C, Hsu JF, Gudeman V, et al. Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1. *J Virol* 2005;79(8):4927-4935.

Publicover J, Ramsburg E, Rose JK. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. *J Virol* 2005;79(21):13231-13238.

Reimann KA, Li JT, Veazey R, Halloran M, Park IW, Karlsson GB, et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. *J Virol* 1996;70(10):6922-6928.

Reimann KA, Li JT, Voss G, Lekutis C, Tenner-Racz K, Racz P, et al. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity

to a chimeric simian/human immunodeficiency virus in rhesus monkeys. *J Virol* 1996;70(5):3198-3206.

Renkema GH, Manninen A, Saksela K. Human immunodeficiency virus type 1 Nef selectively associates with a catalytically active subpopulation of p21-activated kinase 2 (PAK2) independently of PAK2 binding to Nck or beta-PIX. *J Virol* 2001;75(5):2154-2160.

Richman DD, Wrinn T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. *Proc Natl Acad Sci U S A* 2003;100(7):4144-4149.

Robert-Guroff M, Kaur H, Patterson LJ, Leno M, Conley AJ, McKenna PM, et al. Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. *J Virol* 1998;72(12):10275-10280.

Roberts A, Kretzschmar E, Perkins AS, Forman J, Price R, Buonocore L, et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. *J Virol* 1998;72(6):4704-4711.

Robinson HL. New hope for an AIDS vaccine. *Nat Rev Immunol* 2002;2(4):239-250.

Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. *Cell* 2001;106(5):539-549.

Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW, Jr., Vasquez GM, et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. *J Virol* 1998;72(10):7992-8001.

Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman R, et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. *J Virol* 2002;76(17):8875-8889.

Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. *J Virol* 2002;76(14):7306-7321.

Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. *Science* 1999;283(5403):857-860.

Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. *Nat Med* 1999;5(2):204-210.

Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. *Annu Rev Med* 2004;55:355-372.

Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. *Nature* 2002;415(6869):331-335.

Silvera P, Richardson MW, Greenhouse J, Yalley-Ogunro J, Shaw N, Mirchandani J, et al. Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein. *J Virol* 2002;76(8):3800-3809.

Someya K, Cecilia D, Ami Y, Nakasone T, Matsuo K, Burda S, et al. Vaccination of rhesus macaques with recombinant *Mycobacterium bovis* bacillus Calmette-Guerin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. *J Virol* 2005;79(3):1452-1462.

Srivastava IK, Stamatatos L, Kan E, Vajdy M, Lian Y, Hilt S, et al. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. *J Virol* 2003;77(20):11244-11259.

Srivastava IK, VanDorsten K, Vojtech L, Barnett SW, Stamatatos L. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. *J Virol* 2003;77(4):2310-2320.

Staprans SI, Feinberg MB. The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines. *Expert Rev Vaccines* 2004;3(4 Suppl):S5-32.

Stott EJ, Almond N, Kent K, Walker B, Hull R, Rose J, et al. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus. *J Gen Virol* 1998;79 (Pt 3):423-432.

Subbramanian RA, Kuroda MJ, Charini WA, Barouch DH, Costantino C, Santra S, et al. Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys. *J Virol* 2003;77(18):10113-10118.

Takeda A, Igarashi H, Nakamura H, Kano M, Iida A, Hirata T, et al. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model. *J Virol* 2003;77(17):9710-9715.

Tardif MR, Tremblay MJ. Presence of host ICAM-1 in human immunodeficiency virus type 1 virions increases productive infection of CD4+ T lymphocytes by favoring cytosolic delivery of viral material. *J Virol* 2003;77(22):12299-12309.

Tatt ID, Barlow KL, Nicoll A, Clewley JP. The public health significance of HIV-1 subtypes. *Aids* 2001;15 Suppl 5:S59-71.

Tonini T, Barnett S, Donnelly J, Rappuoli R. Current approaches to developing a preventative HIV vaccine. *Curr Opin Investig Drugs* 2005;6(2):155-162.

Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. *Nat Med* 2005;11(6):615-622.

Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. *J Virol* 1995;69(11):6609-6617.

Ugolini S, Mondor I, Parren PW, Burton DR, Tilley SA, Klasse PJ, et al. Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. *J Exp Med* 1997;186(8):1287-1298.

Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. *Science* 1998;280(5362):427-431.

Veazey RS, Lackner AA. HIV swiftly guts the immune system. *Nat Med* 2005;11(5):469-470.

Veazey RS, Tham IC, Mansfield KG, DeMaria M, Forand AE, Shvetz DE, et al. Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. *J Virol* 2000;74(1):57-64.

Vernazza PL, Eron JJ, Fiscus SA, Cohen MS. Sexual transmission of HIV: infectiousness and prevention. *Aids* 1999;13(2):155-166.

Vogel TU, Reynolds MR, Fuller DH, Vielhuber K, Shipley T, Fuller JT, et al. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in

long-term control of simian immunodeficiency virus SIVmac239. *J Virol* 2003;77(24):13348-13360.

Voss G, Manson K, Montefiori D, Watkins DI, Heeney J, Wyand M, et al. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. *J Virol* 2003;77(2):1049-1058.

Wang B, Lal RB, Dwyer DE, Miranda-Saksena M, Boadle R, Cunningham AL, et al. Molecular and biological interactions between two HIV-1 strains from a coinfecting patient reveal the first evidence in favor of viral synergism. *Virology* 2000;274(1):105-119.

Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. *Nature* 2003;422(6929):307-312.

Whatmore AM, Cook N, Hall GA, Sharpe S, Rud EW, Cranage MP. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. *J Virol* 1995;69(8):5117-5123.

Whitney JB, Ruprecht RM. Live attenuated HIV vaccines: pitfalls and prospects. *Curr Opin Infect Dis* 2004;17(1):17-26.

Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, Desrosiers RC. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. *J Virol* 1999;73(10):8356-8363.

Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. *Science* 1998;280(5371):1884-1888.

Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. *AIDS Res Hum Retroviruses* 2002;18(16):1207-1217.

Yang X, Lee J, Mahony EM, Kwong PD, Wyatt R, Sodroski J. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. *J Virol* 2002;76(9):4634-4642.

Yang X, Tomov V, Kurteva S, Wang L, Ren X, Gorny MK, et al. Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1. *J Virol* 2004;78(23):12975-12986.

Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. *Annu Rev Immunol* 1999;17:51-88.

Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. *Science* 2003;302(5647):1056-1060.

Zhang H, Huang Y, Fayad R, Spear GT, Qiao L. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles. *J Virol* 2004;78(15):8342-8348.

Zhao J, Pinczewski J, Gomez-Roman VR, Venzon D, Kalyanaraman VS, Markham PD, et al. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen. *J Virol* 2003;77(15):8354-8365.

Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. *Nat Rev Immunol* 2004;4(3):199-210.

Zwick MB, Bonnycastle LL, Menendez A, Irving MB, Barbas CF, 3rd, Parren PW, et al. Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12. *J Virol* 2001;75(14):6692-6699.

Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. *J Virol* 2001;75(22):10892-10905.